Dr. Panegyres, Director of Neurodegenerative Disorders Research, has no relevant financial relationships to disclose.)
Dr. Greenlee of the University of Utah School of Medicine has no relevant financial relationships to disclose.)
Whipple disease is a treatable, multisystem disease caused by infection with Tropheryma whipplei. Primarily considered a gastrointestinal disorder, the organism also invades joints, heart, skin, eyes, and the endocrine and nervous system. Rarely, Whipple disease of the brain may occur as a primary neurologic disorder without multisystem involvement. Cognitive changes, supranuclear gaze palsy, altered consciousness, myoclonus, seizures, and ataxia occur. Oculomasticatory myorhythmia and oculofacioskeletal myorhythmia are pathognomonic signs. Isolated Whipple disease also mimics glioma. PET studies are useful in evaluating atypical MRI; diffusion restriction might also be a useful marker of progression and response to treatment. The author of this article emphasizes the importance of molecular techniques, particularly polymerase chain reaction, to identify and confirm the diagnosis and evaluate therapy. Antibiotic treatment results in improvement with a sustained remission in the majority of patients.
• Whipple disease of the central nervous system may be primary (ie, without evidence of disease outside of the brain) or secondary, occurring in the context of a multi-system condition.
• The neurologic features of primary and secondary Whipple disease of the brain are diverse and overlap.
• Antibiotics can successfully treat Whipple disease of the brain and prevent fatal infection.
Historical note and terminology
Whipple disease is caused by Tropheryma whipplei (T whipplei) and was first described in 1907.
The content you are trying to view is available only to logged in, current MedLink Neurology subscribers.
If you are a subscriber, please log in.
If you are a former subscriber or have registered before, please log in first and then click select a Service Plan or contact Subscriber Services. Site license users, click the Site License Acces link on the Homepage at an authorized computer.